-

Enochian Biosciences Inc. Shareholder Notice: Robbins LLP is Investigating Enochian Biosciences Inc. (ENOB) on Behalf of Shareholders

SAN DIEGO--(BUSINESS WIRE)--Shareholder rights law firm Robbins LLP is investigating Enochian Biosciences Inc. (NASDAQ: ENOB) and its officers and directors to evaluate whether they violated securities laws or breached fiduciary duties by overstating the Company's commercial prospects for its product pipeline. Enochian is a pre-clinical stage biotechnology company that purportedly researches and develops pharmaceutical and biological products for the human treatment of human immunodeficiency virus, hepatitis B virus, influenza and coronavirus infections, and cancer.

If you would like more information about our investigation of Enochian Biosciences Inc.'s misconduct, click here.

What is this Case About: According to a class action complaint filed against Enochian, Enochian and its top management have credited Dr. Serhat Gumrukcu, Enochian's co-founder and largest shareholder, as a "genius" and the "inventor" of the technology and science behind the Company's product pipeline. However, defendants failed to disclose to shareholders that Gumrukcu had no verifiable degrees beyond high school and therefore, the scientific and technological underpinnings of Enochian's product pipeline purportedly invented by Gumrukcu were dubious at best. As such, defendants significantly overstated the commercial prospects for the Company's product pipeline. Further, Gumrukcu had a criminal history, including fraud, of which Enochian's senior leadership was aware.

On May 25, 2022, the U.S. Department of Justice announced that Gumrukcu had been arrested and charged in a murder-for-hire conspiracy. On this news, the price of Enochian's stock fell almost 37%, to close at $3.70 per share on May 25, 2022. Then, on June 1, 2022, Hindenburg Research published a report on Enochian highlighting the murder-for-hire plot, as well as the other crimes committed by Gumrukcu. Specifically, Gumrukcu "was arrested based on accusations of falsely posing as a doctor" in Turkey in 2012, and "[i]n February 2017, Gumrukcu was arrested by authorities after the State of California accused him of a slew of white-collar crimes, including fraud, identify theft, and check kiting – a total of 14 felonies." On this news, Enochian's stock fell another 28.42%, to close at $3.765 per share on June 1, 2022.

Next Steps: If you acquired shares of Enochian Biosciences Inc. between September 24, 2020 and May 31, 2022, you have legal rights. Contact Robbins LLP for more information about your legal options.

All representation is on a contingency fee basis. Shareholders pay no fees or expenses.

Contact us to learn more:

Aaron Dumas
(800) 350-6003
adumas@robbinsllp.com
Shareholder Information Form

About Robbins LLP: A recognized leader in shareholder rights litigation, the attorneys and staff of Robbins LLP have been dedicated to helping shareholders recover losses, improve corporate governance structures, and hold company executives accountable for their wrongdoing since 2002. To be notified if a class action against Enochian Biosciences Inc. settles or to receive free alerts when corporate executives engage in wrongdoing, sign up for Stock Watch today.

Attorney Advertising. Past results do not guarantee a similar outcome.

Contacts

Aaron Dumas
Robbins LLP
5040 Shoreham Place
San Diego, CA 92122
adumas@robbinsllp.com
(800) 350-6003
www.robbinsllp.com

Robbins LLP

NASDAQ:ENOB

Release Summary
Robbins LLP is investigating whether Enochian and its officers and directors overstated the Company's commercial prospects for its product pipeline.
Release Versions
$Cashtags

Contacts

Aaron Dumas
Robbins LLP
5040 Shoreham Place
San Diego, CA 92122
adumas@robbinsllp.com
(800) 350-6003
www.robbinsllp.com

Social Media Profiles
More News From Robbins LLP

Stockholder Alert: Robbins LLP Informs Investors of the Hyliion Holdings Corp. Class Action

SAN DIEGO--(BUSINESS WIRE)--Robbins LLP informs investors that a securities class action has been filed on behalf of persons and entities that purchased or otherwise acquired Hyliion Holdings Corp. (NYSE: HYLN) securities between May 12, 2026 and June 23 2026, inclusive (the "Class Period"). Hyliion is a power generator company whose primary product is the KARNQ Power Module. The complaint alleges that Hyliion misled investors regarding the viability of its partnership with VFH Holdings LLC. In...

Stockholder Alert: Robbins LLP Informs Investors of the Flotek Industries, Inc. (FTK) Class Action

SAN DIEGO--(BUSINESS WIRE)--Shareholder rights law firm Robbins LLP informs investors that a class action was filed on behalf of all persons and entities who purchased or otherwise acquired Flotek Industries, Inc. (NYSE: FTK) securities between August 3, 2026 and August 17, 2026 (the "Class Period"). Flotek is an energy technology and services company.The complaint alleges that Flotek misled investors by failing to disclose the cancellation of its $400m Puerto Rican deal.Investors who suffered s...

Robbins LLP Encourages WSE Stockholders with Large Losses to Seek Counsel for the Securities Class Action Lawsuit Against Wise Group plc

SAN DIEGO--(BUSINESS WIRE)--Robbins LLP reminds investors that a securities class action has been filed on behalf of all persons and entities that purchased or otherwise acquired Wise Group plc (NASDAQ: WSE) securities between May 11, 2026 and July 23, 2026 (the "Class Period").The complaint alleges that Wise and certain of its senior executives violated the federal securities laws by making materially false and/or misleading statements regarding the Company's anti-money laundering compliance, a...
Back to Newsroom